丁香园 | 丁香通 | 丁香人才 | 丁香会议    点击次数:

Human antibodies from transgenic animals

转载请注明来自丁香园
发布日期:2009-02-18 10:06 文章来源:<a href='http://www.dxy.cn'>丁香园</a>
关键词: 抗体 新药 转基因   点击次数:

作者:Lonberg, N.
单位:Medarex, 521 Cottonwood Drive, Milpitas, CA 95035, USA.
期刊:Nature Biotechnology

Abstract

Laboratory mice provide a ready source of diverse, high-affinity and high-specificity monoclonal antibodies (mAbs). However, development of rodent antibodies as therapeutic agents has been impaired by the inherent immunogenicity of these molecules.

One technology that has been explored to generate low immunogenicity mAbs for in vivo therapy involves the use of transgenic mice expressing repertoires of human antibody gene sequences. This technology has now been exploited by over a dozen different pharmaceutical and biotechnology companies toward developing new therapeutic mAbs, and currently at least 33 different drugs in clinical testing - including several in pivotal trials - contain variable regions encoded by human sequences from transgenic mice. The emerging data from these trials provide an early glimpse of the safety and efficacy issues for these molecules.

Nevertheless, actual product approval, the biggest challenge so far, is required to fully validate this technology as a drug discovery tool. In the future, it may be possible to extend this technology beyond rodents and use transgenic farm animals to directly generate and produce human sequence polyclonal sera.


全球部分在研mAb(包含转基因小鼠生产的蛋白片段)

全文请见“丁香园讨论”

请点这里参加丁香园论坛讨论 >>

编辑: jurgen    作者:Lonberg, N.


以下网友留言只代表网友个人观点,不代表网站观点



请输入验证码: